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Abstract
Background: Methotrexate (MTX) intolerance is a frequent problem of long-term treatment in juvenile idiopathic
arthritis (JIA). Mutations in the methylentetrahydrofolate reductase (MTHFR) gene may increase toxicity of MTX,
potentially constituting an initial stimulus for this conditioned response. The objective of this study was to investigate
the relationship of common MTHFR gene mutations and occurrence of MTX intolerance in pediatric patients with JIA
treated with MTX.
Methods: Consecutive JIA patients on at least 3 months of MTX treatment were included in this study. Intolerance to
MTX was determined using the Methotrexate Intolerance Severity Score (MISS) questionnaire, and MTX intolerance was
defined as MISS values of≥ 6. Presence of the two most common mutations in the MTHFR gene (C677T and A1298C)
was tested using a PCR assay. Results were analyzed using descriptive and non-parametric statistics.
Results: 196 patients were included (73 % female). Of those, 93 (46 %) showed MTX intolerance. 168 patients were
genotyped for C677T and A1298C. MTX intolerance was not found to be significantly more frequent among patients
with hetero- and homozygous or homozygous mutations C677T or A1298C compared to wild type or heterozygous
mutations. Analysis of the correlation between numbers of mutations in these two loci to the MISS score did not yield
a statistically significant correlation.
Conclusion: Mutations in the MTHFR gene were not found to be significantly more frequent in JIA patients intolerant
to MTX. Toxicity associated with the MTHFR gene seems to result from mechanisms different to those involved in
clinical MTX intolerance.
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Introduction
Methotrexate (MTX) has become the mainstay of treat-
ment of polyarticular JIA in the course of the last
25 years [1]. Low-dose treatment with MTX shows few
serious side effects, limited mostly to transient hepato-
toxicity and bone marrow suppression in JIA [2, 3]. The
most common side effects leading to MTX discontinu-
ation in clinical practice are gastrointestinal symptoms
including intolerance in the form of aversion, nausea
and vomiting [4]. Clinical MTX intolerance often takes
the form of anticipatory and associative nausea, a com-
mon side effect also observed among cancer patients [5].
A recent survey demonstrated that up to one half of
pediatric JIA patients are affected by these symptoms,
leading to refusal and premature discontinuation [6].
Hence, the majority of cases of MTX intolerance
appear to constitute a conditioned response. However, it
is possible that a subclinical toxicological effect might be
the root cause of the symptom complex. Two mutations
in the gene for methylene tetrahydrofolate reductase
(MTHFR), C667T and A1298C, are the most common
cause of toxicity in high-dose MTX therapy, as these
mutations lead to delayed drug clearance [7].
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The objective of this study was to investigate associa-
tions between MTHFR gene mutations and MTX in-
tolerance in patients with JIA.
Methods
Consecutive patients seen at the German Center for
Pediatric and Adolescent Rheumatology from October
2012 until December 2014 were included in this study
after written confirmation of informed consent. The
study was approved by the ethics committee of the
Bayerische Landesärztekammer, Munich, Germany. In-
clusion criteria were 1) diagnosis of JIA [8] and 2) treat-
ment with MTX for at least 3 months prior to inclusion.
Exclusion criteria were other conditions associated with
nausea and/or abdominal complaints, and concomitant
medications possibly inducing nausea (excluding bio-
logics and non-steroidal anti-inflammatory drugs). The
following data were extracted from patient medical re-
cords: age, gender, body weight and height, age at diag-
nosis, duration of disease, methotrexate dose, route of
administration, folic acid supplementation (yes/no). In
addition, liver function tests (GOT/GPT) were docu-
mented (elevated/within normal range) as well as treat-
ment with non-steroidal anti-inflammatory drugs
(NSAID) and TNFα-antagonists (TNFA).
Intolerance to MTX was measured using the Metho-
trexate Intolerance Severity Score (MISS) questionnaire,
which has previously been validated for use in JIA [6].
This questionnaire consists of four domains: abdominal
pain, nausea, vomiting and behavioral symptoms, and re-
cords symptoms before (anticipatory) and after MTX ad-
ministration, as well as associative symptoms (i.e.,
symptoms occurring when thinking about MTX). Symp-
toms are assessed at the time of answering the question-
naire, with no specific time frame given. Behavioral
symptoms include restlessness, irritability and refusal of
MTX in response to gastrointestinal symptoms. Each of
the 12 items of the MISS scale is scored on a Likert scale
(0 = no symptoms, 1 =mild symptoms, 2 =moderate
symptoms; 3 = severe symptoms) for a maximum score
of 36. As previously suggested, MTX intolerance was de-
fined as ≥ 6 points on the MISS questionnaire, including
at least one anticipatory, associative or behavioral symp-
tom [9]. DNA was prepared from peripheral mono-
nuclear cells using standardized protocols. Presence of
the two most common mutations in the MTHFR gene
(C677T and A1298C) was assayed using polymerase
chain reaction, as described previously [7, 10].
Demographic and clinical data were analyzed using de-
scriptive statistics. Associations of demographic or treat-
ment factors with MTHFR genotypes were analyzed using
univariate statistics (chi-squared test, Student’s t-test),
where appropriate. Correlation between age and MTX
dose per square meter body surface area (MTX dose/m2
BSA) was calculated using Pearson’s correlation coefficient.
MTHFR mutations were analyzed directly and also grouped
in categories by the amount of mutations in the two loci,
using univariate non-parametric statistics (chi-squared test
and Kruskal-Wallis test). For the latter, we assumed that 0,
1 and 2 mutations correspond to a locus with two alleles in
which 0 and 2 are homozygous and 1 is heterozygous.
Number of mutations in these two gene loci has previously
been associated with MTX toxicity before [11].
Results
Demographic data of the 196 patients included in the
study as shown in Table 1. There were 90 (90/196 =
46 %) patients who were considered MTX intolerant
(MISS: median 11, range 6–32). Table 2 shows uni-
variate analysis of demographic and clinical factors on
presence of MTX intolerance. Disease duration was
significantly associated with occurrence of MTX in-
tolerance. No other factors showed any significant
correlation, although there were non-significant corre-
lations with age, duration of MTX treatment and folic
acid supplementation. Higher doses of MTX were
non-significantly correlated with a lower frequency of
MTX intolerance (p = 0.026); there was an inverse
correlation between age and MTX dose/m2 BSA (r2 =
0.788, p < 0.001)
DNA analyses were done in 168 patients to determine
C677T and A1298C genotypes. Demographic and clinical
factors were also analyzed on these patients alone, with
similar results (Additional file 1: Tables S3 and S4). Among
these, 40 % of patients were heterozygous, and 8 % homo-
zygous for the C677T mutation of the MTHFR gene, 48 %
of patients were heterozygous, and 14 % homozygous for
the A1298C mutation; these allele frequencies are compar-
able to published data [12, 13].
Compared to the homozygous wild type, MTX
intolerance was not found significantly more frequently
in patients with hetero- and homozygous (46 % vs. 54 %,
p = 0.285) or homozygous (9 % vs. 8 %, p = 1.000) C677T
mutations, nor in patients with hetero- and homozygous
(64 % vs.58 %, p = 0.436) or homozygous (16 % vs. 11 %,
p = 0.386) A1298C mutations. Compound heterozygous
Table 1 Demographic and clinical data of study participants
Patients (n = 196)
Age (median, range) 10,7 years (3,1–17,9 years)
Female gender (%) 141 (72 %)
Disease duration (median, range) 3,8 years (15,9-0,5 years)
Duration of MTX treatment (median, range) 1,2 years (13,2- 0,3 years)
Patients with MTX intolerance (%) 90 (45,9 %)
Patients on folic acid 184 (94 %)
Patients on folic acid with MTX intolerance 84 (93 %)
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mutations for C677T and A1298C were also not signifi-
cantly more frequent in patients with MTX intolerance
(15 % vs. 17 %, p = 0.845) (Fig. 1). Analysis of the correl-
ation between number of mutations to the MISS score did
not yield a statistically significant correlation (p = 0.441)
(Fig. 2).
Discussion
This study demonstrates no correlation between two
common mutations in the MTHFR gene and MTX in-
tolerance in a large cohort of JIA patients. Mutations
were not found more frequently in patients with MTX
intolerance, nor was there any correlation between MISS
score and number of mutations in the MTHFR gene.
Disease duration was significantly longer in patients with
MTX intolerance, and non-significant trends also showed
correlation to age and duration of MTX treatment, which
is not surprising. A non-significant trend toward less
MTX intolerance with higher MTX doses can be
explained by a clear inverse correlation between dose and
age, where children at younger ages are dosed more
aggressively. The observation that older age at diagnosis
alone is not correlated with MTX intolerance is interest-
ing in itself: one might expect that older children are more
readily affected by a purely psychological effect.
MTX intolerance is much more frequent in younger
patients than in adults [14]. It mostly occurs within the
first year of treatment and worsens over time [15]. MTX
intolerance in the form of anticipatory or associated
nausea and vomiting has all the hallmarks of a condi-
tioned response, where an originally neutral stimulus
presented in conjunction with an unconditioned stimu-
lus leads to a conditioned response even in the absence
of the unconditioned stimulus [16]. In chemotherapy,
the unconditioned stimulus clearly is drug-induced nau-
sea; however, in low-dose MTX therapy nausea is infre-
quent, and cases of anticipatory nausea are possible
despite lack of post-MTX nausea [6, 17]. Anticipatory
nausea in other antirheumatic drugs is uncommon, des-
pite similar rates of post-treatment nausea [18]. It is
therefore reasonable to assume another, covert uncondi-
tioned stimulus as the cause of MTX intolerance.
MTX is rapidly metabolized and in low-dose therapy
reaches levels of less than 5 μmol/l within 24 h [19].
Mutations in the MTHFR gene cause elevated levels of
Table 2 Influence of demographic and clinical data on MTX
intolerance
MTX tolerant MTX intolerant p
Female Gender 74/106 67/90 0. 525
Age 9,67 ± 4,42 10,83 ± 3,89 0. 055
Age at diagnosis 5,53 ± 4,09 5,13 ± 4,04 0. 495
Disease duration 4,14 ± 3,54 5,70 ± 3,78 0. 003*
Duration of MTX treatment 1,83 ± 2,33 2,45 ± 2,32 0. 064
MTX dose/m2 BSA 12,29 ± 2,08 11,63 ± 2,00 0. 026
s.c. dosing 47/106 40/90 1. 000
Folic acid supplementation 103/106 81/90 0. 069
Elevated LFT 18/106 22/90 0. 217
Treatment with TNFA 47/106 33/90 0. 309
Treatment with NSAID 37/106 31/90 1. 000
BSA body surface area, LFT liver function tests, TNFA TNFα antagonist, NSAID
non-steroidal anti-inflammatory drug
* significant after Bonferroni correction
Fig. 1 MISS scores and mutations in the C677T and A1298C loci in JIA patients on MTX. Compound and non-compound heterozygous patients are
shown in the right. The numbers shown indicate p-values of the corresponding univariate analysis
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MTX in children with high-dose therapy, and in conse-
quence, a higher and more prolonged exposure to MTX
[20]. The most frequent mutations in the MTHFR gene,
C677T and especially A1298 C, are associated with a
higher toxicity in children and adults treated with high-
dose MTX therapy [20, 21]. Influence of MTHFR on
toxicity in patients treated with low-dose MTX treat-
ment (10–15 mg/m2/week) is reported in some popula-
tions, but a recent meta-analysis found no clear
correlation [22–24]. The C677T and A1298C mutations
in the MTHFR gene also lead to higher plasma homo-
cysteine levels, and homocysteine plasma levels have
been shown to increase according to the number of mu-
tations in an individual [11]. However, the lack of associ-
ation between mutations in the MTHFR gene and MTX
intolerance in this study render elevated levels of MTX
and homocysteine unlikely candidates as an uncondi-
tioned stimulus in MTX intolerance.
Patients frequently receive antiemetics and a variety of
home remedies in conjunction with MTX intake which
might have confounded the results of this study. However,
an analysis of the same patients published elsewhere
showed no significant effect of these countermeasures
[25]. C677T and A1298C are only two mutations in the
MTX metabolism pathway, although they are by far the
most common. It is possible that other genetic mutations
in the pathway might be associated with MTX intolerance;
a variety of mutations have been tested on a similar, but
smaller population with no association [15]. The complete
lack of association of the two most common mutations
shown in this study renders a significant contribution to
MTX intolerance by less frequent mutations unlikely. The
overall strength of this study is the prospective investiga-
tion of a large population of JIA patients, allowing confi-
dence in ruling out possible associations between these
two loci and MTX intolerance.
In conclusion, mutations in the MTHFR gene, and by
extension levels of MTX and homocysteine, do not play
a role in the genesis of MTX intolerance. Further studies
are necessary to elucidate the unconditioned stimulus
underlying the conditioned response to MTX that affects
a large proportion of JIA patients on this medication.
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